You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, by visiting http://brodsky-smith.com/1116-cphd-cepheid.html, or calling toll free 877-LEGAL-90. Separately, on July 31, Canaccord’s Mark Massaro reiterated a Hold rating on the stock and has a price target of $36.
Advertisement
Several other brokerages have also weighed in on CPHD. TheStreet cut shares of Cepheid from a “hold” rating to a “sell” rating in a report on Monday, June 6th.
The buoyancy in the outlook of Cepheid (CPHD) is getting weaker by the somewhat negative sentiment (2.2 on a 5-point scale) that sell-side analysts have provided concerning it. Brokerage firms on the average advocate the company shares as Overweight. The company has a consensus rating of “Hold” and an average target price of $41.58. The total traded volume was 3,844,479 shares. The number of shares now owned by investors are 1.96 bln. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
This story is the sole property of American Banking News and it was originally published by American Banking News.
Congratulations are in order to Cepheid’s long-term investors. KS raised its position in shares of Cepheid by 4.2% in the second quarter. Granahan Investment Management Inc.
Cepheid is now covered by 20 Wall Street analysts. The year to date performance is at 13.27% with a 52 week high of -3.80% and a 52 week low of 29.49%. The consensus price target (PT) of $39.83 means that the market expects Company shares to increase by 15.72% in the short run.
Let’s have a look at some of the important valuation ratios of the CEPHEID (NASDAQ:CPHD).
The company posted revenue of $539m last year, which could rise to $635m this year, according to Danaher. The firm’s quarterly revenue was up 10.2% compared to the same quarter a year ago. The company’s revenue was up 16.6% compared to the same quarter a year ago. The EPS growth for the last 5 years is at 7.70% while the predicted EPS growth for the next 5 years is at 0.75%.
Cepheid is a leading and innovative global molecular diagnostics company that develops, manufactures, and markets accurate and easy to use molecular systems and tests.
Advertisement
A bigger healthcare company overpaying for a small-scale biotech stock is precisely why investors love to play in this segment of the market. Cepheid’s fully automated GeneXpert® systems facilitate rapid, sophisticated genetic testing and provide test results for the administration of infectious diseases, among many clinical applications.
